{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:31:37Z","timestamp":1768782697618,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T00:00:00Z","timestamp":1139875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Diabetic dyslipidaemia with decreased high\u2010density lipoprotein\u2010cholesterol (HDL\u2010C) concentration plays a key role in enhanced atherosclerosis. The antioxidant effect of HDL is due to the influence of human paraoxonase 1 (PON1) and several authors have described decreased activity of this enzyme in Type 2 diabetics and subjects with metabolic syndrome. The goal of this study was to examine the effect of daily ciprofibrate on serum PON1 and lipoprotein concentrations in patients with metabolic syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty\u2010one patients with metabolic syndrome were enrolled into the study. We examined the effect of 100\u2003mg\u2003day<jats:sup>\u22121<\/jats:sup> ciprofibrate treatment on lipid concentrations, oxidized low\u2010density lipoprotein (LDL), PON1 concentrations and activity. We also investigated the calculated size of LDL\u2010cholesterol (LDL\u2010C).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the 3\u2010month study, it was observed that following treatment with ciprofibrate, the serum triglyceride concentration decreased significantly (from 2.76\u2003\u00b1\u20030.9\u2003mmol l<jats:sup>\u22121<\/jats:sup> to 2.27\u2003\u00b1\u20031.6\u2003mmol\u2003l<jats:sup>\u22121<\/jats:sup>; \u221218%; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), while HDL\u2010C increased significantly (from 0.95\u2003\u00b1\u20030.2\u2003mmol\u2003l<jats:sup>\u22121<\/jats:sup> to 1.2\u2003\u00b1\u20030.3\u2003mmol\u2003l<jats:sup>\u22121<\/jats:sup>; 26%; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). The oxidatively modified LDL\u2010C concentration decreased significantly (from 137\u2003\u00b1\u200319\u2003U\u2003l<jats:sup>\u22121<\/jats:sup> to 117\u2003\u00b1\u200320\u2003U\u2003l<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), while HDL\u2010associated apolipoprotein A1 significantly increased (from 1.35\u2003\u00b1\u20030.2\u2003g\u2003l<jats:sup>\u22121<\/jats:sup> to 1.75\u2003\u00b1\u20030.3\u2003g\u2003l<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). The LDL\u2010C\/LDL\u2010apoB ratio, which reflects the size of LDL, increased significantly (from 0.96\u2003\u00b1\u20030.05 to 1.05\u2003\u00b1\u20030.06; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Serum PON1 activity was significantly elevated (from 108\u2003\u00b1\u200334\u2003U\u2003l<jats:sup>\u22121<\/jats:sup> to 129\u2003\u00b1\u200331\u2003U\u2003l<jats:sup>\u22121<\/jats:sup>; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05), while standardized values for HDL\u2010C remained significantly unchanged (PON1\/HDL\u2010C) (from 114\u2003\u00b1\u200321 to 107\u2003\u00b1\u200320; NS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Three months of treatment with ciprofibrate favourably affected the lipid profile, increased LDL resistance to oxidation and improved antioxidant status by increasing serum paraoxonase activity in these patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2006.02565.x","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T10:07:24Z","timestamp":1139911644000},"page":"694-701","source":"Crossref","is-referenced-by-count":19,"title":["Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome"],"prefix":"10.1111","volume":"61","author":[{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Seres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annam\u00e1ria","family":"Erdei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Audikovszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00f3r\u00e1nd","family":"Debreczeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kov\u00e1csay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Illy\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyula","family":"Pados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90550-I"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5978.276"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1972.tb00676.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)38659-4"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.68.7.60"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(86)90296-6"},{"key":"e_1_2_6_8_2","first-page":"228","article-title":"Lipid abnormalities in insulin resistant states","volume":"4","author":"Watson KE","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80962-3"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)05524-M"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.16.10.1243"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119134"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(91)90215-O"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.7.2257"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92709-3"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00728-0"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118869"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80682-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(80)90213-0"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200019040-00005"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70077-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-004-0104-8"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030648"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00034-3"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.11.1812"},{"key":"e_1_2_6_26_2","first-page":"2338","article-title":"The polymorphic paraoxonase\/arylesterase isozymes of human serum","volume":"43","author":"La Du BN","year":"1984","journal-title":"Fed Proc"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200001000-00022"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP39551"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90866-7"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000174541"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.23308"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)05378-V"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403271200"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030191"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(96)05859-5"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90246-3"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00003-3"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M200452-JLR200"},{"key":"e_1_2_6_39_2","first-page":"83","article-title":"Changes in paraoxonase and apolipoprotein A\u2010I, B, C\u2010III and E in subjects with combined familial hyperlipoproteinaemia treated with ciprofibrate","volume":"26","author":"Turay J","year":"2000","journal-title":"Drug Exp Clin Res"},{"key":"e_1_2_6_40_2","first-page":"604","article-title":"Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of beneficial action of fibrates?","volume":"27","author":"Balogh Z","year":"2001","journal-title":"Diab Met"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.4.945"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115532"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116541"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030191"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2006.02565.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2006.02565.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:48:49Z","timestamp":1697424529000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2006.02565.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,14]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1365-2125.2006.02565.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02565.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,14]]}}}